Testing effectiveness (Phase 2)Study completedNCT01842321What this trial is testingAbiraterone Acetate in Molecular Apocrine Breast CancerWho this might be right forBreast Cancer UNICANCER 34
Large-scale testing (Phase 3)Active Not RecruitingNCT04191499What this trial is testingA Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerWho this might be right forBreast Cancer Hoffmann-La Roche 325
Early research (Phase 1)WithdrawnNCT06590558What this trial is testingTesting the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast CancerWho this might be right forAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+9 more National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Ended earlyNCT01697293What this trial is testingPTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast CancerWho this might be right forBreast AdenocarcinomaEstrogen Receptor PositiveHER2/Neu Negative+6 more Prescient Therapeutics, Ltd. 34
Testing effectiveness (Phase 2)Study completedNCT01527487What this trial is testingTrial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast CancerWho this might be right forHER2 Negative Breast Cancer SCRI Development Innovations, LLC 76
Not applicableStudy completedNCT01461044What this trial is testingAn Observational Study of Avastin (Bevacizumab) in Patients With HER2-metastatic or Locally Advanced Breast CancerWho this might be right forBreast Cancer Hoffmann-La Roche 228
Testing effectiveness (Phase 2)Looking for participantsNCT06224673What this trial is testingARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast CancerWho this might be right forHER2 Low Breast CarcinomaTriple Negative Breast CancerHormone-receptor-positive Breast Cancer+1 more Laura Huppert, MD, BA 36
Testing effectiveness (Phase 2)UnknownNCT02983071What this trial is testingG1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerWho this might be right forCarcinoma, Ductal, BreastBreast CancerBreast Neoplasm G1 Therapeutics, Inc. 102
Testing effectiveness (Phase 2)Ended earlyNCT03584009What this trial is testingA Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor TherapyWho this might be right forEstrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer Hoffmann-La Roche 103
Testing effectiveness (Phase 2)Study completedNCT05340413What this trial is testingPredicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.Who this might be right forHER2-negative Breast CancerMetastatic Breast CancerTriple Negative Breast Cancer SOLTI Breast Cancer Research Group 65
Testing effectiveness (Phase 2)Active Not RecruitingNCT02957968What this trial is testingNeoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast CaWho this might be right forBreast AdenocarcinomaEstrogen Receptor- Negative Breast CancerEstrogen Receptor-positive Breast Cancer+10 more Virginia Commonwealth University 46
Not applicableActive Not RecruitingNCT05955521What this trial is testingExosome as the Prognostic and Predictive Biomarker in EBC PatientsWho this might be right forTriple Negative Breast CancerHER2-positive Breast Cancer Samsung Medical Center 200
Large-scale testing (Phase 3)Active Not RecruitingNCT02107703What this trial is testingAbemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast CancerWho this might be right forBreast Neoplasms Eli Lilly and Company 669
Large-scale testing (Phase 3)Not Yet RecruitingNCT05172518What this trial is testingUtidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast CancerWho this might be right forBreast NeoplasmsLocally Advanced or Metastatic Breast Cancer Sun Yat-sen University 512
Testing effectiveness (Phase 2)Study completedNCT01698918What this trial is testingOpen-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast CancerWho this might be right forHormone Receptor Positive Breast Cancer Novartis Pharmaceuticals 202
Post-approval studies (Phase 4)UnknownNCT05809024What this trial is testingSelect the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine TherapyWho this might be right forLocally Advanced Breast CancerHormone Receptor Positive,HER2-negative Breast Cancer Yongsheng Wang 100
Testing effectiveness (Phase 2)Ended earlyNCT00959946What this trial is testingStudy Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast CancerWho this might be right forAdvanced Breast Cancer (Parts 1 and 2)Advanced Pancreatic Cancer (Part 1)Advanced Colorectal Cancer (Part 1)+2 more Pfizer 32
Large-scale testing (Phase 3)Active Not RecruitingNCT02115282What this trial is testingExemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or MetastaticWho this might be right forAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Breast Adenocarcinoma+4 more National Cancer Institute (NCI) 608
Testing effectiveness (Phase 2)Study completedNCT05445908What this trial is testingSKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast CancerWho this might be right forTriple-negative Breast Cancer and HR+/HER2- BC Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 184
Testing effectiveness (Phase 2)Looking for participantsNCT04585750What this trial is testingThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)Who this might be right forAdvanced Solid TumorAdvanced Malignant NeoplasmMetastatic Cancer+27 more PMV Pharmaceuticals, Inc 300